Out­pace Bio ex­pands cell ther­a­py R&D, nets re­search col­lab­o­ra­tions in Seat­tle

Out­pace Bio, a Seat­tle-based biotech that aims to cre­ate cell ther­a­pies, has ce­ment­ed its pres­ence in the Emer­ald City with a new fa­cil­i­ty and a pair of lo­cal re­search part­ner­ships with sci­en­tif­ic lead­ers.

The biotech an­nounced Tues­day that it se­cured a new fa­cil­i­ty in a 23,000-square-foot space in Seat­tle’s Dex­ter Yard to house the com­pa­ny’s R&D ef­forts. The com­pa­ny now has 53 em­ploy­ees and has grown from a plat­form com­pa­ny to a pipeline and plat­form com­pa­ny, both of which re­quire growth and more space, ac­cord­ing to Out­pace CEO Marc La­joie in an in­ter­view with End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER